KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

@article{Blank2011KRASAB,
  title={KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.},
  author={Patricia R Blank and Holger Moch and Thomas D. Szucs and Matthias Michael Schwenkglenks},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 19},
  pages={
          6338-46
        }
}
PURPOSE Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab, have led to significant clinical benefits for metastatic colorectal cancer (mCRC) patients but have also increased treatment costs considerably. Recent evidence associates KRAS and BRAF mutations with resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab treatment of chemorefractory mCRC patients. EXPERIMENTAL… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 57 REFERENCES

KRASMutationsstatus–pr€ adiktiver Marker zur Antik€ orper-Therapie bei Cost-effectiveness of KRAS/BRAF Testing in mCRC www.aacrjournals.org Clin Cancer Res

  • WA BodePeter
  • on April
  • 2011

Similar Papers

Loading similar papers…